Interestingly, in a study utilising melanoma cells from patients who relapsed following treatment with BRAF or MEK targeted inhibitors, treatment with the FAK inhibitor (FAKi) defactinib was able to resensitise cells to killing by MAPK pathway inhibition (Del Mistro et al., 2022). The gene discussed is BRAF; the disease is melanoma.